AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12679900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative transcatheter arterial chemoembolization (TACE)
Number of subjects: 0
Study 12679900 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative transcatheter arterial chemoembolization (TACE)
Number of subjects: 0
Study 12679900 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Number of subjects: 0
Study 12679900 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy using LAK cells
Number of subjects: 0
Study 12679900 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon α and Interferon β
Number of subjects: 0
Study 12679900 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclic retinoic acid
Number of subjects: 0
Study 15090417 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% autologous serum drops
Number of subjects: 16
Study 15090417 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 16
Study 10396714 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 3027
Study 10396714 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg droperidol
Number of subjects: 3027
Study 10396714 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis (ondansetron or droperidol)
Number of subjects: 3027
Study 10396714 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized outcome feedback
Number of subjects: 3027
Study 10396714 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis
Number of subjects: 3027
Study 10396714 — intervention group
Group type: EXPERIMENTAL
Intervention: PROT selection
Number of subjects: 3027
Study 10396714 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 3027
Study 7562289 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity program (group EX; n = 13), consisting of range of motion with passive resistance to all extremities for 5 to 10 minutes daily
Number of subjects: 26
Study 7562289 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C; n = 13)
Number of subjects: 26
Study 2256469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (CS) at low doses (not exceeding 5 mg/kg/day)
Number of subjects: 0
Study 2256469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (CS)
Number of subjects: 0
Study 7378228 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-gauge Teflon cannulae
Number of subjects: 333
Study 7378228 — intervention group
Group type: COMPARATOR
Intervention: Other cannula types
Number of subjects: 333
Study 28392142 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-13 booster
Number of subjects: 62
Study 28392142 — intervention group
Group type: COMPARATOR
Intervention: PCV-13
Number of subjects: 62
Study 26316025 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-1 (level 1) attended an educational group session (EGS) on the Mediterranean diet (MD)
Number of subjects: 0
Study 26316025 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-2 (level 2) attended an EGS and received additional support
Number of subjects: 0
Study 26316025 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sample from both groups
Number of subjects: 0
Study 26316025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of food intake during intervention
Number of subjects: 0
Study 23335178 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 DNA methylation score (mean methylation in L1 and any methylation in L2)
Number of subjects: 84
Study 21392068 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy
Number of subjects: 344
Study 21392068 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined motivational enhancement and cognitive behaviour therapy
Number of subjects: 344
Study 21392068 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 344
Study 20307457 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injection to heel
Number of subjects: 45
Study 20307457 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic block to tibial nerve
Number of subjects: 45
Study 20307457 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 45
Study 17338716 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker or cardioverter‐defibrillator implantation
Number of subjects: 150
Study 17338716 — intervention group
Group type: COMPARATOR
Intervention: Baseline ICV
Number of subjects: 150
Study 15569121 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus clausii (2 x 10(9) spores, t.d.s. for 14 days)
Number of subjects: 120
Study 15569121 — intervention group
Group type: COMPARATOR
Intervention: Placebo (t.d.s. for 14 days)
Number of subjects: 120
Study 11512649 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 20 microg x kg(‐1)
Number of subjects: 4
Study 11512649 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 25 microg x kg(‐1)
Number of subjects: 4
Study 11512649 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 30 microg x kg(‐1)
Number of subjects: 4
Study 11512649 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil 10 microg x kg(‐1) and suxamethonium 1 mg x kg(‐1)
Number of subjects: 4
Study 11512649 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 4
Study 11512649 — intervention group
Group type: EXPERIMENTAL
Intervention: Group SSA (alfentanil 10 microg x kg(‐1) and suxamethonium 1 mg x kg(‐1))
Number of subjects: 4
Study 9780987 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic splenectomy (LS)
Number of subjects: 82
Study 9780987 — intervention group
Group type: COMPARATOR
Intervention: Open splenectomy (OS)
Number of subjects: 82
Study 8172150 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at bedtime for 2 months
Number of subjects: 16
Study 8172150 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at bedtime for 2 months
Number of subjects: 16
Study 3280795 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF) at a daily dose of 4 mg
Number of subjects: 58
Study 3280795 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF) at a daily dose of 6 mg
Number of subjects: 58
Study 3280795 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF) at a daily dose of 8 mg
Number of subjects: 58
Study 3280795 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF) at a daily dose above 6 mg
Number of subjects: 58
Study 3280795 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment with Auranofin (AF)
Number of subjects: 58
Study 31117810 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924
Study 31117810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study 27792836 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g paracetamol
Number of subjects: 80
Study 27792836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 26353031 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab plus IVIG
Number of subjects: 190
Study 26353031 — intervention group
Group type: COMPARATOR
Intervention: Placebo/IVIG
Number of subjects: 190
Study 23356772 — intervention group
Group type: EXPERIMENTAL
Intervention: GAKIC (10.2 g)
Number of subjects: 9
Study 23356772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 23356772 — intervention group
Group type: EXPERIMENTAL
Intervention: GAKIC
Number of subjects: 9
Study 20617887 — intervention group
Group type: EXPERIMENTAL
Intervention: First presentation of items
Number of subjects: 0
Study 20617887 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated presentations of items
Number of subjects: 0
Study 20617887 — intervention group
Group type: EXPERIMENTAL
Intervention: New items
Number of subjects: 0
Study 20617887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical regions (left retrosplenial/posterior cingulate cortex and right lateral occipito-temporal cortex)
Number of subjects: 0
Study 20617887 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral mid-intraparietal sulcus and precuneus
Number of subjects: 0
Study 18854418 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent renal replacement therapy (IRRT)
Number of subjects: 316
Study 18854418 — intervention group
Group type: COMPARATOR
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 316
Study 17823012 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular injections
Number of subjects: 0
Study 17823012 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia with or without femoral nerve block (TKA patients)
Number of subjects: 0
Study 15183925 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and glucose drink (68 g carbohydrate and 38 mg caffeine)
Number of subjects: 56
Study 15183925 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and glucose drink (68 g carbohydrate and 46 mg caffeine)
Number of subjects: 56
Study 15183925 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and glucose drink (60 g carbohydrate and 33 mg caffeine)
Number of subjects: 56
Study 15183925 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 56
Study 12427583 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with medically-based psychosocial intervention
Number of subjects: 0
Study 12427583 — intervention group
Group type: COMPARATOR
Intervention: Placebo with medically-based psychosocial intervention
Number of subjects: 0
Study 9814488 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute oral water load test (20 mL/kg BW) in patients with water retention
Number of subjects: 17
Study 9814488 — intervention group
Group type: COMPARATOR
Intervention: Acute oral water load test (20 mL/kg BW) in normal subjects
Number of subjects: 17
Study 9814488 — intervention group
Group type: EXPERIMENTAL
Intervention: UAQP‐2 levels in patients with water retention
Number of subjects: 17
Study 9814488 — intervention group
Group type: COMPARATOR
Intervention: UAQP‐2 levels in normal subjects
Number of subjects: 17
Study 9814488 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal urinary osmolality in patients with water retention
Number of subjects: 17
Study 9814488 — intervention group
Group type: COMPARATOR
Intervention: Minimal urinary osmolality in normal subjects
Number of subjects: 17
Study 9814488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone replacement in patients with hypopituitarism
Number of subjects: 17
Study 9814488 — intervention group
Group type: EXPERIMENTAL
Intervention: UAQP‐2 levels after hydrocortisone replacement in patients with hypopituitarism
Number of subjects: 17
Study 9814488 — intervention group
Group type: COMPARATOR
Intervention: UAQP‐2 levels in control subjects
Number of subjects: 17
Study 7897461 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation Activities Profile (RAP) assessment
Number of subjects: 0
Study 2612550 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐F 5 mg b.d.
Number of subjects: 12
Study 2612550 — intervention group
Group type: EXPERIMENTAL
Intervention: ER‐F 10 mg o.d.
Number of subjects: 12
Study 2612550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 745897 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rehearsal only
Number of subjects: 32
Study 745897 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rehearsal with simulated dart-throwing motor movements
Number of subjects: 32
Study 745897 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct physical practice
Number of subjects: 32
Study 745897 — intervention group
Group type: COMPARATOR
Intervention: No-practice controls
Number of subjects: 32
Study 31526039 — intervention group
Group type: EXPERIMENTAL
Intervention: MediYoga
Number of subjects: 132
Study 31526039 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 132
Study 31526039 — intervention group
Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 132
Study 31116468 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments/interventions in physiological research studies
Number of subjects: 0
Study 31116468 — intervention group
Group type: EXPERIMENTAL
Intervention: Less biased approaches for estimating the proportion of responders
Number of subjects: 0
Study 26001567 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine 0mg twice a day
Number of subjects: 0
Study 26001567 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 1.5mg twice a day
Number of subjects: 0
Study 26001567 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine 3mg twice a day
Number of subjects: 0
Study 23860506 — intervention group
Group type: EXPERIMENTAL
Intervention: Young Athletes (YA) intervention group
Number of subjects: 233
Study 23860506 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 233
Study 22097126 — intervention group
Group type: EXPERIMENTAL
Intervention: Pizhen manipulation
Number of subjects: 83
Study 22097126 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 83
Study 19781326 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 66
Study 19781326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 16756730 — intervention group
Group type: EXPERIMENTAL
Intervention: Velocity port
Number of subjects: 40
Study 16756730 — intervention group
Group type: COMPARATOR
Intervention: classic titanium port
Number of subjects: 40
Study 15315849 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplex vaccine
Number of subjects: 22365
Study 15315849 — intervention group
Group type: EXPERIMENTAL
Intervention: diTeBooster vaccine
Number of subjects: 22365
Study 15315849 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 22365
Study 11535983 — intervention group
Group type: EXPERIMENTAL
Intervention: PTX plus carboplatin
Number of subjects: 0
Study 11535983 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin alone
Number of subjects: 0
Study 11535983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CP) + PTX
Number of subjects: 0
Study 11535983 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CP) alone
Number of subjects: 0
Study 9311648 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate suppositories (200 mg/capsule) given rectally at 0, 4, 8, 12, 24, 36, 48, and 60 hr (total = 1,600 mg) followed by oral mefloquine (750 mg at 72 hr and 500 mg at 84 hr)
Number of subjects: 63
Study 9311648 — intervention group
Group type: COMPARATOR
Intervention: Artesunate suppositories (200 mg/capsule) given rectally at 0, 12, 24, 36, 48, and 60 hr (total = 1,200 mg) followed by oral mefloquine (750 mg at 72 hr and 500 mg at 84 hr)
Number of subjects: 63
Study 8110401 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-based solution without electrolytes (Group A)
Number of subjects: 22
Study 8110401 — intervention group
Group type: COMPARATOR
Intervention: Rice-based solution with electrolytes (Group B)
Number of subjects: 22
Study 2437278 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose gammaglobulin 400 mg/kg/d for 3 days plus aspirin 30 mg/kg/d
Number of subjects: 136
Study 2437278 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone at the same dosage (30 mg/kg/d)
Number of subjects: 136
Study 31380660 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminiscing and Emotion Training (RET)
Number of subjects: 248
Study 31380660 — intervention group
Group type: COMPARATOR
Intervention: Community Standard (CS)
Number of subjects: 248
Study 31380660 — intervention group
Group type: COMPARATOR
Intervention: Nonmaltreating comparison condition
Number of subjects: 248
Study 29685870 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet- and mobile-based stress intervention group
Number of subjects: 150
Study 29685870 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 150
Study 26669827 — intervention group
Group type: EXPERIMENTAL
Intervention: Target Inhalation Mode (TIM)
Number of subjects: 21
Study 26669827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal Breathing Mode (TBM)
Number of subjects: 21
Study 26669827 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 77 mg of A1-PI
Number of subjects: 21
Study 24671858 — intervention group
Group type: EXPERIMENTAL
Intervention: MMD (midazolam-meperidine-dexmedetomidine)
Number of subjects: 110
Study 24671858 — intervention group
Group type: COMPARATOR
Intervention: midazolam-meperidine
Number of subjects: 110
Study 22644357 — intervention group
Group type: EXPERIMENTAL
Intervention: Epineural buprenorphine 0.15 mg
Number of subjects: 150
Study 22644357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular buprenorphine 0.15 mg
Number of subjects: 150
Study 22644357 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 150
Study 20412135 — intervention group
Group type: EXPERIMENTAL
Intervention: AIC-treated (n=17)
Number of subjects: 32
Study 20412135 — intervention group
Group type: COMPARATOR
Intervention: Placebo-treated (n=15)
Number of subjects: 32
Study 20412135 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 18616367 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO+) until surgical closure of the soft palate at the age of +/- 52 weeks
Number of subjects: 54
Study 18616367 — intervention group
Group type: COMPARATOR
Intervention: No intervention (IO-)
Number of subjects: 54
Study 18616367 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant orthopedics (IO+)
Number of subjects: 54
Study 15165913 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbofilm-coated stent
Number of subjects: 420
Study 15165913 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel stent
Number of subjects: 420
Study 11481927 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice (0.243% sodium fluoride in a silica base and dicalcium phosphate dihydrate)
Number of subjects: 2432
Study 11481927 — intervention group
Group type: COMPARATOR
Intervention: Positive Control Dentifrice (0.243% sodium fluoride in a silica base)
Number of subjects: 2432
Study 11481927 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice
Number of subjects: 2432
Study 11481927 — intervention group
Group type: COMPARATOR
Intervention: Positive Control Dentifrice
Number of subjects: 2432
Study 9513627 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 180
Study 9513627 — intervention group
Group type: COMPARATOR
Intervention: Standard Counseling
Number of subjects: 180
Study 8063978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychotherapy (CB)
Number of subjects: 117
Study 8063978 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic-interpersonal psychotherapy (PI)
Number of subjects: 117
Study 2494098 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 180
Study 2494098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 791333 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol 1.0‐2.0 mg/kg intravenously
Number of subjects: 20
Study 791333 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 10 mg intravenously
Number of subjects: 20
Study 31637435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene Index (SHI)
Number of subjects: 202
Study 31637435 — intervention group
Group type: EXPERIMENTAL
Intervention: Morningness‐Eveningness Questionnaire (MEQ)
Number of subjects: 202
Study 31637435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene practices
Number of subjects: 202
Study 31637435 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological health interventions
Number of subjects: 202
Study 31637435 — intervention group
Group type: COMPARATOR
Intervention: Sleep patterns (bedtime and wake time)
Number of subjects: 202
Study 31637435 — intervention group
Group type: COMPARATOR
Intervention: Sleep patterns (bedtime stress)
Number of subjects: 202
Study 31637435 — intervention group
Group type: COMPARATOR
Intervention: Sleep patterns (planning/worrying in bed)
Number of subjects: 202
Study 30952158 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25mg base/kg) plus primaquine (0.5 mg/kg/day for 14 days)
Number of subjects: 680
Study 30952158 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25mg base/kg) plus primaquine (1 mg/kg/day for 7 days)
Number of subjects: 680
Study 30952158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (dihydroartemisinin 7mg/kg and piperaquine 55mg/kg) plus primaquine (0.5 mg/kg/day for 14 days)
Number of subjects: 680
Study 30952158 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (dihydroartemisinin 7mg/kg and piperaquine 55mg/kg) plus primaquine (1 mg/kg/day for 7 days)
Number of subjects: 680
Study 30952158 — intervention group
Group type: COMPARATOR
Intervention: 14-day high-dose primaquine regimen
Number of subjects: 680
Study 30952158 — intervention group
Group type: COMPARATOR
Intervention: 7-day high-dose primaquine regimen
Number of subjects: 680
Study 30952158 — intervention group
Group type: EXPERIMENTAL
Intervention: G6PD female heterozygotes
Number of subjects: 680
Study 28938439 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg metformin with cholecystokinin (0.4 pmol × kg‐1 × min‐1)
Number of subjects: 15
Study 28938439 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg metformin without cholecystokinin
Number of subjects: 15
Study 28938439 — intervention group
Group type: COMPARATOR
Intervention: Placebo with cholecystokinin
Number of subjects: 15
Study 28938439 — intervention group
Group type: COMPARATOR
Intervention: Placebo without cholecystokinin
Number of subjects: 15
Study 25945045 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC 250 (salmeterol 50 mcg and fluticasone propionate 250 mcg)
Number of subjects: 52
Study 25945045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 25945045 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC 250
Number of subjects: 52
Study 22404879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy (MBT) consisting of eight 1-hour sessions over 4 weeks
Number of subjects: 16
Study 22404879 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy (MBT)
Number of subjects: 16
Study 21701060 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 9